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patient charts were identified (mean age: 41.2yrs; female:67%; currently treated 
with DMTs: 601(85%); discontinued DMTs in past 3 months: 35(5%); DMT-naive: 
35(10%). Of the 601 currently treated patients, current line of DMT: 1st-line-62%, 
2nd-line-28%, > = 3rd-line-10%. 1st-line patient characteristics included- mean 
age:40.0yrs; female:69%; average time-to-initiation of DMT from diagnosis:7.5mo; 
time on current 1st-line DMT:51.5months; JCV status: positive-1%/negative-7%/
don’t know-8%/not tested-84%. Top-4 reason for 1st-line DMT initiation: efficacy 
against relapses(25%), efficacy in early MS(25%), efficacy in slowing disease pro-
gression(18%), patient decision(12%). Mean EDSS-score:1.65; current disability (per-
physician-judgment): mild-81%/moderate-17%/severe-2.2%. 2nd-line DMT patient 
characteristics included- mean age:42.8yrs; female:66%; average time-to-initiation 
of DMT from diagnosis:3.7mo; time on current 2nd-line DMT:31.2months; JCV status: 
positive-14%/negative-26%/don’t know-8%/not tested-52%. Top-4 reason for choos-
ing the 2nd-line DMT: efficacy against relapses(34%), efficacy in slowing disease pro-
gression(34%), patient decision(8%), tolerability(7%); correspondingly, top-4 reasons 
for switch from 1st-line DMTs were: lack of efficacy(38%), relapse(24%), flu-like symp-
toms(17%), injection-site reactions(11%). Mean EDSS-score:2.98; current disability 
(per-physician-judgment): mild-50%/moderate-44%/severe-7%. ConClusions: In 
this cohort, RRMS patients on 2nd-line DMT appear to have higher disease burden 
compared to those on 1st-line DMT. Time-to-initiation of first DMT after diagnosis 
differed significantly between these two groups. Further research is warranted to 
scrutinize the observed treatment patterns and treatment sequencing strategies 
to alleviate patient burden.
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objeCtives: Due to a rapidly aging population, age-related diseases, such as 
Alzheimer’s disease (AD), are becoming a great concern in China. The objective of 
this study was to provide an overview of the future socio-economic issues raised by 
the increasing prevalence of AD in China. Methods: A literature review was done 
to collect information on the disease management, the demographic projections, 
and medical capabilities available in China. To answer the questions that emerged 
from the literature review, five clinical experts and two hospital administrative 
payers were interviewed. Results: It was estimated that there were 10 million 
cases of AD in China in 2010. As a typical aging disease, the burden of AD in China 
is substantial and will continue growing as the elderly population grows. Around 
33% of the Chinese population is expected to be older than 60 in 2050, representing 
438 million people. A large imbalance was found between AD management needs 
and availability of health care services for AD patients, as a result of: 1> Chinese 
culture values family care for the elderly, while the single-child policy resulting 
in 4 grand-parents and 2 parents being cared for by one child, 2> extremely poor 
awareness of AD in China both publicly and privately (assimilated as dementia), and 
3> limited medical capabilities for AD. As a result, it is predicted that working-age 
Chinese population will have to take time to provide informal care for the elderly, 
leading to an important impact on the productivity. ConClusions: Results suggest 
China is an emerging market for AD treatments. There is a large imbalance between 
AD management needs and capabilities to provide it in China.
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objeCtives: The Brazilian public health system (SUS) provides donepezil, rivastig-
mine and galantamine for all individuals with Alzheimer’s disease (AD). The Ministry 
of Health (MoH) is responsible for the acquisition of rivastigmine and donepezil, 
whereas the States are responsible for the acquisition of galantamine, reimbursed 
by MoH. The aim of this study is to characterize patients with AD and the financial 
resources employed by the MoH. Methods: Descriptive analysis of the profile of 
patients and drug expenses, based on data about the amount dispensed and values 
reimbursed by the MoH in 2012, avaliable in the database of the SUS (current values; 
exchange rate: US$ 1 = R$ 2.36). Were considered: a) MoH expenses with central 
acquisition of donepezil and rivastigmine and b) values of galantamine reimburse-
ment. Results: In 2012, 119,378 patients with AD were treated with medicines in 
the SUS. These patients had a mean age of 78.57 years and 65.87% were women. Most 
of them was treated with rivastigmine (42.98%), followed by donepezil (39.07%) and 
galantamine (17.95%). The annual costs per patient with galantamine were 17 times 
higher than donepezil (US$ 1,045.07 with galantamine, US$ 439.78 with rivastigmine 
and US$ 61.47 with donepezil). The MoH expenses in this period with these drugs 
summed up to US$ 14,176,227.12. This amount represented 0.73% of the total MoH´s 
budget of high-cost drugs in 2012. The biggest expenses occurred with rivastigmine 
(76.16%), followed by donepezil (12.09%) and galantamine (11.74%). ConClusions: 
Despite the higher cost of treatment with galantamine, the impact with rivastigmine 
was greater because it is the most common drug. The central acquisition of drugs 
results in lower treatment cost due to its scale economy and the public development 
partnerships results, a strategy aimed to strengthen the health industrial complex, 
the resource optimization and the access to medicines.
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drug treatment treatment, polytherapy, low mean seizure free interval, male gen-
der, presence of ADR and high mean duration of disease are significantly (P < 0.05) 
associated with low HRQoL scores. ConClusions: Epilepsy has a negative impact 
on their HRQoL. The determinants found by this study will help in framing different 
strategies to improve patient’s compliance and their HRQoL.
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objeCtives: Little evidence exists on the impact of herpes zoster (HZ ) on qual-
ity of life (QoL) and work absenteeism for immunocompromised patients. This 
study describes work absenteeism, and loss in quality of life due to HZ among 
immunocompromised individuals in the United States, UK, Canada, France and 
Germany. Methods: A web-based survey was conducted with adult males and 
females who: 1) had cancer or stem cell transplant (SCT) and HZ (HZ and cancer 
group); 2) cancer or SCT without HZ (cancer group); and 3) had neither cancer, SCT or 
HZ (immunocompetent group). Validated measures included the Brief Pain Inventory 
(BPI), activities of daily living (ADL), the EQ-5D-5L, and the World Health Organization 
Health and Work Performance Questionnaire (WHO HPQ) for work absenteeism. 
Multivariable logistic regressions controlling for demographic characteristics and 
comorbidities examined the impact of HZ on the EQ-5D-5L score and absenteeism 
relative to the cancer and immunocompetent groups. Results: Overall, there were 
353 respondents with HZ (HZ and cancer group), 351 with cancer only, and 353 
were immunocompetent. HZ patients had average pain scores that were at least 
2 and 3 points greater (p< 0.001) than the cancer and immunocompetent groups, 
respectively. Across all ADLs, HZ patients scored 4 and 5 points higher (p< 0.001) 
than the cancer and immunocompetent groups, respectively. HZ patients had 2 
and 20 more hours of absenteeism than the cancer and immunocompetent (p= 0.06) 
groups; and scored 0.5 and 7.3 points lower on the EQ-5D-5L than the cancer and 
immunocompetent (p= 0.01) groups. ConClusions: HZ respondents had greater 
pain, more absenteeism and lower EQ-5D-5L scores than those without HZ. Despite 
the differences between the HZ and cancer groups on ADLs and pain, these groups 
reported similar scores on the EQ-5D-5L, suggesting the EQ-5D-5L may not be sensi-
tive enough to capture the impact of HZ.
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objeCtives: Triptans have been used widely as acute treatments for migraine. 
This study aimed to determine distinct characteristics of triptan users and non-
users, identify socioeconomic-related factors associated with triptan use, define 
migraine utilization patterns and ascertain differences in cost between triptan and 
non triptan users in migraine patients. Methods: This study used the Medical 
Expenditure Panel Survey (MEPS) household component files for panels 11-14 (years 
2006-2010). Subjects who had a migraine diagnosis and were 18 years or older were 
included in the sample. Triptan users were identified from prescribed medicines 
files. Predictors associated with triptan use in migraineurs were assessed by mul-
tivariate logistic regression. Health care expenses (per person per year) including 
medical care and prescription drug expenses were measured from the payer per-
spective. The association between health expenses and triptan use was examined by 
multivariate linear regression. Results: We identified 1,644 eligible subjects in our 
study, representing 36.7 million individuals during 2006-2010 in the United States. 
Nearly 30% of the subjects received triptans to treat migraine. The triptan users 
were more likely to be women, white and have college degrees than non-users. The 
subjects receiving triptans had higher total numbers of office visits and prescription 
drug fills but lower number of emergency department visits than those not. The 
triptan expense accounted for 47% of migraine-related expenses in one year. After 
adjustment, triptan users showed 26% higher total all-cause health care expenses 
than non-users. ConClusions: Socioeconomic factors such as gender, race, educa-
tion and income levels might influence triptan use in migraineurs. Triptan treatment 
impacts on migraine-related expenses and is associated with increased total health 
care expenses in subjects with migraine.
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objeCtives: To assess treatment dynamics and disease burden among RRMS 
patients currently treated with DMTs in the US. Methods: A multi-center medi-
cal chart-review study of MS patients was conducted in 4Q2012 among neurologists 
to collect de-identified data. Neurologists were screened for duration of practice 
(> = 3yrs) and patient volume (> = 15 MS patients/month) and recruited from a large 
panel to be geographically representative of the US. Medical charts of next 10 con-
secutive MS patients were abstracted by each neurologist to collect patient diag-
nosis, treatment patterns and symptomatology/disability-status. RRMS patients 
currently treated with 1st-line & 2nd-line DMTs were evaluated. Results: 708 RRMS 
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Overall, clinicians’ preferences for drugs delivered via intrathecal pumps were 
driven by patient-related health factors.
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objeCtives: To assess health care provider (HCP) perception of barriers to pre-
scribing medications to patients with Multiple Sclerosis (MS) in EU and the 
US. Methods: A multi-country HCP survey was conducted in 5EU (UK/Germany/
France/Spain/Italy) and the US as part of a retrospective chart-review study of MS 
patients. HCPs (mostly physicians) were screened for experience (> = 3yrs) and 
patient volume (> 15MS patients/month) and recruited from a large HCP-panel to 
be geographically representative in each country. Practice characteristics, HCP per-
ceptions and practice patterns were assessed. HCP perceptions of the following 
barriers to prescribing interferons (all types), glatiramer acetate, natalizumab and 
fingolimod were assessed: patients prefer other medications (barrier-1), availability/
cost (barrier-2), guidelines/license restrictions (barrier-3) and drug-related issues 
(barrier-4). Summary statistics are reported. Results: In 4Q2012, 360 HCPs (nerol-
ogists:95%; nurses:5% (from UK only)) participated. Mean age (5EU/US):45/50yrs; 
female (5EU/US):34%/21%; years practicing in neurology (5EU/US):16/19yrs; practice-
location (> = 50% of time in hospital-setting; 5EU/US):83%/26%; % HCPs seeing MS 
patients in specialty clinic (5EU/US):53%/27%; % HCPs with MS as the main focus 
area (5EU/US):68%/40%. Geographic distribution of HCPs was: 5EU-72% (UK-16%, 
Germany/France/Spain/Italy-14% each), US-28%. Patient volume/month per HCP 
was (5EU/US): All-patients-254/319, MS-patients-61/68. MS patient-type seen was 
(5EU/US): relapsing-remitting-52%/58%, relapsing secondary progressive-13%/13%, 
non-relapsing secondary progressive-13%/12%, primary progressive-8%/6%, clini-
cally isolated syndrome-9%/7%, benign-6%/4%. Average prescriptions written/month 
for MS-treatments was (5EU/US):51/62. Key barriers to prescribing interferons were 
(5EU/US): barrier-1:12%/13%, barrier-2:11%/21%, barrier-3:9%/8%, barrier-4:55%/56%, 
no-barrier:30%/24%; for glatiramer (5EU/US): barrier-1:14%/12%, barrier-2:9%/18%, 
barrier-3:8%/6%, barrier-4:62%/60%, no-barrier:28%/28%; for natalizumab (5EU/
US): barrier-1:16%/17%, barrier-2:28%/36%, barrier-3:47%/23%, barrier-4:81%/92%, 
no-barrier:15%/5%; for fingolimod (5EU/US): barrier-1:5%/21%, barrier-2:35%/48%, 
barrier-3:49%/21%, barrier-4:65%/84%, no-barrier:17%/4%. ConClusions: Drug-
related issue was the most frequently cited barrier to prescribing MS medications 
both in 5EU and the US. Drug availability/cost and guidelines/license restrictions 
were more often cited by HCPs in the US and 5EU respectively. Impact of these bar-
riers on optimal patient management and outcomes may warrant further research.
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objeCtives: The purpose of this study was to understand how United States payers 
manage novel oral, high cost MS medications in consideration of the availability of 
lower cost injectable treatments, generally considered less convenient regarding 
administration while in line with the efficacy of orals. Methods: The respective 
tier statuses and utilisation management of teriflunomide, fingolimod, dimethyl 
fumarate, interferon beta-1a (AVONEX and REBIF), and glatiramer acetate at 46 plans 
were audited: 18 Medicare, 12 national private (including PBMs), and 16 regional 
and state private plans. Access to oral MS treatments was compared to that of 
injectable MS treatments to identify differences in tiering or utilisation manage-
ment. Results: 54% of plans demonstrated preferential coverage of injectable MS 
therapies over orals, by lower tier status or lighter utilisation management. By seg-
ment, regional and state private plans demonstrated the strongest preference for 
injectables, with 75% of these plans demonstrating this preference compared to 50% 
of Medicare and 33% of national private plans. Plans employing prior authorisation 
or step edits to manage oral MS therapies usually stepped orals through injectables. 
Among oral MS products, national private and Medicare plans tended to prefer 
fingolimod, with 50% and 61% of plans preferring it over at least one other oral MS 
product, respectively. 19% of regional and state private plans preferred dimethyl 
fumarate over at least one other oral MS product. ConClusions: United States pay-
ers take varying approaches to the management of oral MS medications; however, 
virtually no plans offer preferential access to orals over injectables. The sample is 
roughly split between plans preferring injectable MS products over orals and those 
offering roughly parity access.
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objeCtives: Cleft lip with and without cleft palate is the second most prevalent 
birth defect in the United States. Previous epidemiological studies of cleft lip surgery 
have been plagued by multiple design and methodological issues, including failure 
to adjust costs, grouping of cleft lip only (CL) with cleft lip and palate (CLP) diagno-
ses, and improper definition of secondary cleft lip surgery. The objective of this study 
was to provide national estimates of primary and secondary cleft lip surgery using 
cohort definitions based on national treatment guidelines. Methods: The nation-
ally representative Kids’ Inpatient Database (KID) was used for this study. Years 
analyzed included 2003, 2006, and 2009. Subjects were identified by International 
Classification of Diseases Ninth Revision (ICD-9) diagnosis of cleft lip only or cleft 
lip and palate. Primary surgery was defined as a surgery before two years of age with 
the ICD-9 procedural code for cleft lip repair. Secondary surgery was defined as a sur-
objeCtives: The Ontario Drug Policy Research Network has received provincial gov-
ernment funding to conduct research relating to formulary modernization within 
the Ontario Public Drug Programs. This innovative, integrated program for drug 
class reviews incorporates a novel methodological technique called reimbursement-
based economics which focuses on reimbursement strategies. The first class review 
related to triptans for migraines. In Ontario, triptans are currently available through 
the Exceptional Access Program (EAP). Specific research questions related to the 
current evidence for the cost-effectiveness of triptans and the economic impact 
of alternative changes to their funding status. Methods: Systematic review of 
cost-effectiveness studies of triptans focusing on strength and quality of evidence. 
2. Applied, policy-oriented reimbursement based economic model developed to 
forecast budget expenditure for each alternative reimbursement strategy (generic 
pricing, generic substitution, quantity limits and/or more liberal access). Results: 
21 economic studies were identified though many had a number of common limita-
tions reducing their usefulness in aiding decision making. The weight of evidence 
suggests that triptans are more cost effective than ergots, in patients experienc-
ing acute migraine. Maintaining triptans within the EAP with generic equivalents 
costing 25% of branded products reduces expenditure by 18%-85%. Greater access 
to triptans but with a quantity limit of 6 units per month would increase total 
expenditure by between 133%-140%: less restrictive quantity limits would lead to 
expenditure increases of up to 326%. ConClusions: Evidence suggests that, for 
migraine, triptans are cost effective compared to ergots. Allowing greater access to 
triptans would significantly increase expenditure and may lead to use in a wider 
population where neither effectiveness nor cost effectiveness has been established. 
Maintaining triptan coverage through EAP with generic equivalents costing 25% of 
branded products combined with generic substitution will reduce total expendi-
tures by 67%. Other factors will be considered before final recommendations on 
formulary changes are made.
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objeCtives: The first oral disease modifying therapy (DMT) was approved in the fall 
of 2010, the second followed two years later with a short six-month gap before the 
third approval. This study sought to describe and compare patients prescribed one 
of the three oral DMTs available to treat relapsing forms of multiple sclerosis (MS) 
in the US. Methods: Adult patients with a claim for fingolimod, teriflunomide or 
dimethyl fumarate on or after September 22, 2010 (‘index’) were identified in the 
Truven Health MarketScan® databases. Patients had an MS diagnosis (ICD-9-CM 
340) in the 12 months prior to index, continuous enrollment 12 months pre- and 3 
months post-index and a confirmatory claim for their index drug. Demographic, 
clinical and severity characteristics were measured and compared in the 12 month 
baseline period. Results: A total of 3,379 patients were included, mean age 46.3 
(SD 10.5), 75.4% female. The majority (85.8%, n= 2,899) indexed on fingolimod, with 
10.0% (n= 339) indexing on teriflunomide and the remaining 4.2% (n= 141) indexing 
on dimethyl fumarate. Patients indexing on teriflunomide and dimethyl fumarate 
were significantly older than those indexing on fingolimod (50.0 [SD 9.6] and 48.1 
[SD 10.4] vs. 45.8 (SD 10.2), respectively, both p< 0.01). A greater proportion of patients 
indexing on teriflunomide had chronic pain, high blood pressure and high choles-
terol than those indexing on fingolimod (47.2% vs.40.8%, 30.4% vs. 19.7% and 24.5% 
vs. 15.8%, respectively, all p< 0.05) and a greater proportion of patients indexing on 
dimethyl fumarate had arthritis and thyroid disease than those indexing on fin-
golimod (13.5% vs. 6.9% and 13.5% vs. 8.1%, both p< 0.05). ConClusions: Factors 
in the decision to start disease modifying therapy with one of the oral medications 
can be complex. This study showed that older patients with more comorbid disease 
are being channeled to the two newest oral medications on the market.
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objeCtives: Intrathecal drug therapy via implanted pump for treatment of spas-
ticity and chronic pain is highly varied and may have significant implications for 
patient outcomes. The objectives of this study were to: 1) characterize factors 
that influence real-world usage of these drugs, and 2) identify key differences 
and similarities in clinical practice, along with unmet needs across global mar-
kets. Methods: A cohort of 96 health care providers (HCPs) was surveyed across 6 
countries, Canada (16), France (15), Italy (10), Germany (20), UK (15), and US (20). The 
HCPs included physicians and nurses caring for patients with intrathecal pumps 
across multiple specialties. Results: Compounded vs Manufacturer-prepared: 
While respondents cited continued need for compounded drugs (66%), comparable 
manufacturer-prepared drugs, if available, were preferred by at least 33% (highest 
in Germany, 45%), even at a higher procurement cost (20%). Over 25% respondents 
expressed concern over compounded drugs, including limited regulation, vari-
able efficacy, and potential for sterility issues. 1) Dosage: Depending on the drug, 
from 60% to 90% of respondents expressed interest in new manufacturer-prepared 
doses; 2) Packaging Format: Over 77% respondents preferred pre-filled syringes 
over ampules (18%) or vials (5%), largely due to ease of use and sterility. Despite this 
preference, 65% of respondents were concerned about the associated higher cost of 
prefilled syringes. ConClusions: This cross-sectional survey identified consist-
ent themes across the 6 markets. Unmet needs identified included opportunities 
for manufacturer-prepared drugs, new packaging forms, and new concentrations. 
